Ionis Pharmaceuticals Inc (IONS)
Groundbreaking pivotal study results of olezarsen for severe hypertriglyceridemia (sHTG) presented as a late breaker at AHA Scientific Sessions
Groundbreaking pivotal study results of olezarsen for severe hypertriglyceridemia (sHTG) presented as a late breaker at AHA Scientific Sessions
📈 **POSITIVE** • Medium confidence analysis (69%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business